| To view this email as a web page, click here.
|
| Volume VII ▪ Issue V ▪ OncLive®, An MJH Life Sciences™ brand ▪ Est. MCMXCIX |
 |
| Good morning. From our global headquarters in New Jersey, OncLive® delivers the resources and information oncology professionals need to provide the best patient care. In this edition, 2 BTK inhibitors go head-to-head in a CLL trial, while 2 novel checkpoint inhibitors move through the pipelines in esophageal cancer and mucosal melanoma. |
| |
|
| You can follow us here for breaking news on new drug approvals, updates on upcoming events, and new insights from the leading voices in Oncology. |
| |
| Thanks for your continuing support. |
| |
| G. MAURO |
| Editorial Director, OncLive® |
| |
| |
| |
| |
 |
|
Main story |
|
| |
|
First sentence of story. This writeup can be longer than the others. |
|
| |
|
Read More |
|
|
| |
|
| |
| |
Image: 250x180 px |
|
Image: 250x180 px |
|
| |
Headline |
|
Headline |
|
| |
First sentence of story. No more than two lines in this space... |
|
First sentence of story. No more than two lines in this space...
|
|
| |
Read More |
|
Read More |
|
|
| |
|
| |
Image: 250x180 px |
|
Image: 250x180 px |
|
| |
Headline |
|
Headline |
|
| |
First sentence of story. No more than two lines in this space... |
|
First sentence of story. No more than two lines in this space... |
|
| |
Read More |
|
Read More |
|
|
| |
| |
